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Abstract
Background: Viral populations are complex, dynamic, and fast evolving. The evolution of groups of closely related
viruses in a competitive environment is termed quasispecies. To fully understand the role that quasispecies play in viral
evolution, characterizing the trajectories of viral genotypes in an evolving population is the key. In particular, long-
range haplotype information for thousands of individual viruses is critical; yet generating this information is non-trivial.
Popular deep sequencing methods generate relatively short reads that do not preserve linkage information, while third
generation sequencing methods have higher error rates that make detection of low frequency mutations a
bioinformatics challenge. Here we applied BAsE-Seq, an Illumina-based single-virion sequencing technology, to eight
samples from four chronic hepatitis B (CHB) patients – once before antiviral treatment and once after viral rebound
due to resistance.
Results: With single-virion sequencing, we obtained 248–8796 single-virion sequences per sample, which allowed us
to find evidence for both hard and soft selective sweeps. We were able to reconstruct population demographic history
that was independently verified by clinically collected data. We further verified four of the samples independently
through PacBio SMRT and Illumina Pooled deep sequencing.
Conclusions: Overall, we showed that single-virion sequencing yields insight into viral evolution and population
dynamics in an efficient and high throughput manner. We believe that single-virion sequencing is widely applicable to
the study of viral evolution in the context of drug resistance and host adaptation, allows differentiation between soft or
hard selective sweeps, and may be useful in the reconstruction of intra-host viral population demographic history.
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Background
Viral intra-host evolution is a critical obstacle in the
treatment of chronic infectious diseases. It is the root
cause of viral host immune escape and drug resistance,
and consequently a major impediment in disease cure
and eradication [1, 2]. The hepatitis B virus (HBV) is a
prime example. HBV is a small, circular DNA virus. The
HBV polymerase is error prone, with an estimated error
every 105 to 107 bases [3]. When coupled with a large
viral load (often between ~103 copies/ml to 107 copies/
ml of serum), this can give rise to substantial viral diver-
sity in active infections [4]. In other words, a sufficiently
large viral population can potentially carry, or produce
within a short period of time, all possible mutations,
thus providing a genetic reservoir for rapid viral re-
sponse and adaptation [5–10]. Practically, the accumula-
tion of viral mutations is indicative of chronic disease
progression and severity [11–13]. Mutations that quickly
become predominant in the population are also indica-
tors for how the viruses might be circumventing host re-
sponse and treatment that enable fresh approaches for
drug development research [14].
HBV viral populations, specifically those in chronic in-
fections, can be extremely diverse genetically. Part of the
reason is due to high mutation rates leading to the pres-
ence of quasispecies [15–20]. Another contributing factor
may also stem from genetic repositories in the form of
stable covalently closed circular DNA (cccDNA) in in-
fected hepatocytes. Identifying medically important muta-
tions in such populations can become complicated. First,
consensus sequence changes occur relatively slowly. For
HBV, the mean number of nucleotide substitutions is only
estimated at between 1.5 × 10−5 to 7.9 × 10−5 nucleotide
substitutions per site per year [19]. The study of consensus
sequences alone may not reveal underlying quasispecies
dynamics, which may be much more rapid as the popula-
tion constantly explores possible genotypes [20]. Second,
these hidden quasispecies dynamics may be important in
understanding the key indicators of viral fitness. Human
host immune response, host genetics, treatment regimes,
and finally the viral genotype itself likely interact in a com-
plex fashion that exerts multiple, possibly contradictory
selective forces on the virus that ultimately culminates in
clinical outcome. Identifying the relevant subpopulation of
viruses that are reacting to selective pressures of interest,
whether it is nucleoside analogues, interferon treatments,
or a change in host immune response can reveal import-
ant viral indicators for disease progression.
In order to leverage the recent advancements in next
generation sequencing (NGS) technology, we explored
single-virion sequencing as an option for characterizing
quasispecies diversity in active infections. Deep population
sequencing is routinely used to identify polymorphisms,
including extremely rare alleles [21–26]. However, without
linkage information, it remains difficult to describe quasis-
pecies based on allele frequencies alone. A large number
of complete genomes from a single viral population must
be sequenced to be confident of full quasispecies diversity.
Traditionally, such studies require viruses to be individu-
ally cloned and sequenced – a rather tedious process re-
quiring a large amount of work and precious source
material [19, 27]. However, the complexity and import-
ance of quasispecies has never been clearer [28], and there
are two recent next NGS technologies that can be applied
to single-virion sequencing in a high-throughput manner,
promising up to thousands of viral sequences from every
chronic hepatitis B (CHB) patient sample. BAsE-Seq is an
Illumina-based method that makes use of random 20mer
barcodes to tag every single viral genome with a unique
sequence. The barcoded genomes are then amplified as a
single amplicon for library construction [29]. Reads from
BAsE-Seq libraries can be reassembled into individual
viral genomes in silico post sequencing, effectively con-
structing thousands of viral genomes with full haplotype
information. An alternative approach uses single molecule
real time sequencing technology (SMRT) on the Pacific
Biosciences platform (PacBio) to produce long reads for
individual molecules (up to 60 kb). While single pass se-
quencing error rates are high, the relatively small 3 kb
HBV genomes can be read up to dozens of times by the
same polymerase, sharply lowering error rates and yielding
highly accurate genome sequences, with the additional
benefit of not requiring a reference genome [30].
We aimed to apply these single-virion sequencing
methods in a manner tailored to characterizing viral
population diversity, quasispecies structure, and popula-
tion evolution. More specifically, we aimed to discover
additional information on viral evolutionary dynamics not
visible to regular deep sequencing. We picked a relatively
well-understood model – that of HBV resistance to the
antiviral drug Lamivudine - where the most common re-
sistance alleles are well characterized [31], and obtained
two serum samples from each of four CHB patients who
were treated with and subsequently developed resistance
to Lamivudine. We searched for resistance mutations in
each of the patients and tried to reveal additional quasis-
pecies dynamics using single-virion sequencing. We found
that single-virion sequencing reveals vital information
about viral population heterogeneity and fluctuations in
population composition during viral evolution.
Methods
Sample identification and collection in the clinic
Both clonal lab strains and patient samples were used in
this study. Plasmids with clonal HBV sequences (referred
to as Clone-1 and Clone-2 in the text) were constructed
and processed as previously detailed in [28] and se-
quenced as controls. Patient samples were recruited to
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test single-virion sequencing on biological populations
as well as to describe any additional information that
can be gained through haplotype sequencing. Only pa-
tients who gained resistance to Lamivudine with serum
samples of suitably high viral load (>103 viral copy num-
ber/ml) both pre-treatment and post-resistance were
considered. As per standard clinical practice, patients
who stop responding to anti-viral treatment were tested
for resistance mutations through capillary sequencing.
For these patients, viral DNA was extracted from 200 μl
of serum using the Qiagen Blood mini kit, and the ex-
tracted HBV genome was PCR amplified using the
Dynazyme DNA polymerase and the primers [Fwd (5′-
G[T/C]GTAGACTCGTGGTGGACTTCTCTC-3′).
Rev. (5′-TGACA[T/A/G/C]ACTTTCCAATCA AT-3′)].
The amplified 650 bp fragment was purified by gel elec-
trophoresis and extraction, followed by direct sequen-
cing on an ABI 3730XL DNA Analyzers (SI Table 1). 4
patients with gains of resistance mutations totaling 8
time points had serum samples pulled from the data-
base for sequencing.
Barcode-directed assembly for extra-long sequences
(BAsE-Seq)
BAsE-Seq was carried out on all samples. They were:
Clone-1, Clone-2, Patient 1 timepoints 1.1 and 1.2, Patient
2 timepoints 2.1 and 2.2, Patient 7 timepoints 7.1 and 7.2,
and Patient 11 timepoints 11.1 and 11.2. Library prepar-
ation was carried out according to the protocol as de-
scribed in [28]. Briefly, a total of 106 HBV genomes were
subjected to a 2-cycle PCR that assigned unique barcodes
to each strand of the HBV genome. Two rounds of PCR
were carried out to amplify the product, using HBV spe-
cific primers (5′-GCTCTTCTTTTTCACCTCTGCCTAA
TCA-3′ and 5′-GCTCTTCAAAAAGTTGCATGGTGC
TGG-3′), taking care to stay within the exponential ampli-
fication regime during each round of PCR to minimize the
generation of chimeric PCR products [28]. Specifically, a
two-stage PCR protocol was employed such that reactions
were stopped in the log-linear phase. The final amplicon
spans 3175 bp. Samples were exonuclease- digested to
generate a pool of nested deletions fragments, which were
end-repaired and circularized. Circular products were
fragmented and tagged with the Illumina adaptors
followed by 14 cycles of PCR to incorporate primers for
sequencing. The resulting 2 × 101 bp reads were trimmed
for adaptor sequences and base quality with Trimmomatic
[32]. A subset of 10,000 read pairs was first BWA-MEM
(v 0.7.10) mapped to 8 known HBV genotypes A-H one at
a time [33, 34]. All reads were then BWA-MEM mapped
to the genotype reference with the lowest number of
mismatches. At this point, mapped reads with identical
barcodes, signifying their origin from the same viral
molecule, are sorted into individual folders for further
processing. For each barcode, aligned reads were
duplicate-marked, realigned, and recalibrated with GATK
v2.7 [35]. Finally, SNVs were called with LoFreq v2.1.2
[36] and incorporated into the final sequences for each
barcode (Additional file 1: Figure S4, S5, S8). Full-length
viral sequences that passed all quality filters went on to be
part of the population analysis [SI]. Maximum Likelihood
phylogenies were built from the top 100 sequences with
the highest coverage for easier visual interpretation using
FastTree v2.1.8 [37, 38]. PHYLIP Neighbor Joining trees
were constructed [39] from the full set of viral sequences
obtained [SI]. All trees presented were drawn with iTOL
[40, 41]. For further details about the pipeline including all
processing and error filters refer to [SI].
Pooled deep sequencing (Illumina)
Pooled deep sequencing was carried out on Clone-1,
Clone-2, Patient 1 timepoints 1.1 and 1.2, and Patient 2
timepoints 2.1 and 2.2. Insufficient DNA remained from
Patients 7 and patient 11 after BAsE-Seq sequencing,
and these four samples had to be excluded from Pooled
deep sequencing. For a detailed protocol of sample li-
brary preparation, refer to [31]. Briefly, 106 HBV viral
genomes were PCR amplified using the same primers as
Table 1 Patient sample nomenclature and viral copy number
Sample ID Patient Date Viral Copies/ul Single-virion Sequences Nucleotide Diversity ∏
1.1 1 15th Nov 94 378,500 1717†, 1635* 0.0012/base
1.2 1 3rd Jul 99 52,270 3331†, 2514* 0.0024/base
2.1 2 22nd May 95 239,750 391†, 1330* 0.0032/base
2.2 2 29th Aug 97 44,687 3747†, 2504* 0.0013/base
7.1 7 19th May 95 69,180 2647† 0.0022/base
7.2 7 11th Apr 00 48,083 789† 0.0016/base
11.1 11 19th Jun 95 208,275 2754† 0.0211/base
11.2 11 3rd Nov 98 466,200 248† 0.0052/base
†-total number of single-virion sequences obtained from a BAsE-Seq library. *-total number of single-virion sequences obtained from a PacBio library. Nucleotide
diversity Π, the arithmetic mean between all pairwise differences between viral sequences within each viral population, were calculated from BAsE-Seq single-
virion sequences for the entire amplified genomic sequence of 3175 bases (3215 minus the 40 bases that were not amplified)
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in BAsE-Seq that cover all but the first 40 bp of the
3215 bp genome. 2–3 μg of PCR product for each viral
DNA sample was sheared to achieve a fragment size
range between 100 and 300 bp. Library preparation was
performed using the Qiagen GeneRead DNA Library I
Kit according to manufacturer instructions. After end-
repair, A-tailing, and adapter ligation, ligated products in
the 200–400 bp range were gel-extracted, and subjected
to 14 PCR cycles to incorporate multiplexing indices.
The final product was quantified and run on a Illumina
HiSeq 2000 instrument. Resulting Illumina 2 × 101 bp
reads were trimmed by base quality with Trimmomatic
and mapped to the concatenated HBV pan-genome con-
sisting of all 8 major genotypes A-H with BWA-MEM
(Additional file 1: Figure S1, Table S2). All concordantly
mapped read pairs were duplicate-marked, realigned,
and recalibrated with GATK 2.7. SNVs present in the
pool were called based on comparison with the best
match genotype sequence using LoFreq 2.1.2.
PacBio library construction and analysis
PacBio SMRT sequencing was later carried out on
Clone-1, Clone-2, Patient 1 timepoints 1.1 and 1.2, and
Patient 2 timepoints 2.1 and 2,2. Insufficient DNA
remained from Patients 7 and patient 11 after BAsE-Seq
sequencing, and these four samples had to be excluded
from PacBio library construction. 106 HBV viral ge-
nomes were PCR amplified using the same primers as
mentioned above under Pooled Deep Sequencing and
BAsE-Seq. 2–3 μg of PCR product was used for PacBio
library construction following the 2 kb Template Prepar-
ation and Sequencing protocol. Library products were
quantified on Agilent 2100 Bioanalyzer, and run on a
PacBio instrument with V6 chemistry. PacBio raw reads
were first processed with the SMRT Portal analysis
programs. To focus on full length functional viruses,
circular consensus sequences (CCS) from each library
were called with a cutoff of at least 10× subreads within
a polymerase read and a minimum subread length of
2500 bp using the RS_ReadsOfInsert application
(Additional file 1: Figure 2a, b). CCSs were multiple-
sequence aligned against all 8 genotypes with MUSCLE
[42]. Bases within the CCS reads with quality scores <75
were masked as Ns to filter out false positives
(Additional file 1: Figure. 2c), and the resulting (nearly)
full-length viral sequences were BWA-SW mapped as
extremely long reads to the concatenated HBV pan-
genome consisting of all 8 major genotypes A-H
(Additional file 1: Figure 3). (Although a reference panel
is not necessary for PacBio long reads, it was included in
the analysis here for direct comparison between outputs
from the platforms.) Segregating sites within the viral
populations were called with LoFreq 2.1.2 with primer
regions masked. Maximum Likelihood phylogenies were
built from the highest quality 100 CCs sequences of the
correct length (3175 bp) using FastTree v2.1.8. Neighbor
Joining trees were constructed from the full set of viral se-
quences obtained using PHYLIP [SI]. All trees presented
were drawn with iTOL. For a detailed protocol regarding
PacBio read processing and error filters refer to [SI].
Reconstruction of demographic history by BEAST
A Bayesian Markov Chain Monte Carlo (MCMC) ap-
proach was implemented using BEAST v1.8.4 [43] on all
sets of 4 patient samples in order to estimate demo-
graphic and evolutionary parameters, using the Bayesian
skyline plot as a coalescent prior. Unique single-virion
sequences constructed from BAsE-Seq libraries often
carried missing information due to uneven coverage. Be-
cause an excess of ‘N’s can overwhelm the true signal,
only the top 100 sequences with the highest overall
coverage were used for BEAST analysis. A final fragment
of 3134 coding bases was used for demographic history
reconstruction. Samples prior to Lamivudine treatment
were defined as sequences collected on day 0 and sam-
ples post drug resistance annotated as sequences col-
lected n days after. We employed the GTR + Γ4
unlinked codon model of nucleotide substitution and a
strict molecular clock. The MCMC chain length was set
to 1E9 to 2E9 generations, depending on the patient
sample in question, with sampling of every 1E4th. Con-
vergence of the estimates was considered satisfactory
when the effective sample size (ESS), calculated in
Tracer v1.6, was >200 for all parameters. The first 10%
of the estimates was discarded as burn-in. Where neces-
sary, multiple runs were merged using LogCombiner as
part of the BEAST package. Run results were analyzed
and skyline plots, showing changes in effective popula-
tion time over time, generated with Tracer v1.6 [44].
Results
Single-virion sequencing platform error-rates
The three platforms - Pooled Deep sequencing, BAsE-
Seq, and PacBio - were tested on two HBV clones with
known sequences [28] for pipeline construction and
optimization. The data available from each platform is
represented in (Fig. 1). Pipelines tailored to each plat-
form were then applied to viral populations from two
patients (P1 and P2) to gauge single-virion sequencing
performance and throughput on clinical samples [SI].
We began the study with BAsE-Seq, and added PacBio
sequencing libraries as the technology became more ac-
cessible. We sequenced lab clones with know sequences
and estimated the error rates of both methods by sum-
marizing the frequency of base differences in sequenced
haplotypes. The base error rates of BAsE-Seq and PacBio
libraries were between 0.02–0.3 and 0.2–1.3 per kb of
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single-virion sequence respectively, and the error rates
for small indels in BAsE-Seq and PacBio reads were
<0.02/kb and 2.9–3.4/kb respectively. PacBio sequencing
is known to have higher error rates in homopolymer
runs [45]. We tried to further reduce PacBio error rates
through careful selection of PCR polymerase [Additional
file 1: Figure S2a-b] and CCS quality filters [Additional file
1: Figure S2c], but still faced multiple sequence alignment
issues that gave false positive single nucleotide variants
(SNVs) [Additional file 1: Figure S3]. As PacBio errors are
random and thus low in frequency when consolidated
across all reads, we bypassed this issue by mapping CCs
reads to a reference sequence [Additional file 1 Figure S6–
S7, S9–S13], and only considering these positions in our
population analysis. Because PacBio is a reference inde-
pendent sequencing technology, it is also possible to map
Fig. 1 Graphical representation of sequence reads obtained from BAsE-Seq, PacBio, and Pooled Deep sequencing. X-axis: Genome position. Y-axis: Relative
coverage. Each dot represents coverage at a single base position. From left to right: Pooled deep sequencing short reads give uneven genomic coverage.
BAsE-Seq reconstitutes single-virion sequences by mapping barcoded short reads to a reference, thus matching exact reference length but may have
missing information spread throughout depending on local coverage as shown by dips in the coverage plot. PacBio circular consensus reads (CCSs) can
vary in length, but will not necessarily require a reference for construction. A library of 3 kb amplicons will cover the entire genome evenly as shown. Dip
in coverage around 1.5 kb is due to a deletion in the sample
Fig. 2 Genotype composition (Y-axis) of samples sequenced (X-axis) as reported by BWA-SW coverage across 8 reference genotype sequences.
Samples are organized from left to right in order of P1.1, P1.2, P2.1, P2.2, P7.1, P7.2, P11.1, and P11.2, where P1.1 and P1.2 are two time points from
the same patient P1, before and after drug resistance respectively. Wherever data from multiple technologies are available, order follows Pooled
deep sequencing, BAsE-Seq, and lastly PacBio
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reads to a de novo reference sequence generated from the
run. Here, we elected for a common reference sequence
across all samples for ease of comparison across BAsE-
Seq, PacBio, and Pooled deep sequencing data. A more
detailed explanation of all work conducted in this com-
parison exercise is available in Additional file 1.
Classic resistance mutations observed
Serum samples were taken from each patient twice for
viral DNA library construction - once before they were
treated with Lamivudine (labeled as P1.1, P2.1, P7.1,
P11.1) and once after viral loads rebounded to detectable
levels (labeled as P1.2, P2.2, P7.2, P11.2) (Table 1).
The four libraries from patients P1 and P2 were se-
quenced on Pooled Deep sequencing, BAsE-Seq, and
PacBio platforms. The remaining four libraries from pa-
tients P7 and P11 were sequenced and analyzed only by
BAsE-Seq due to limited patient serum availability.
Viral genotype composition in each sample was esti-
mated from the percentage of reads mapping to each
genotype reference in the pan-genome panel. Three out
of four patients carried Genotype B viruses. The only ex-
ception was P11, who carried a mixed Genotype B and
Genotype C infection prior to drug treatment, but only
Genotype C viruses post Lamivudine resistance (Fig. 2).
Illumina short reads tend to mis-map in regions where
sequence divergence is ~3% between the references
Table 2 The frequencies of detected resistance alleles in each
of the 4 patients after drug resistance. None of these mutations
were observed (below detection limit) in the populations prior
to development of resistance
# Mutation Pooled Deep Seq BAsE-Seq PacBio
P1 M204 V
L180 M
M204I
0.525
0.560
0.457
0.711
0.752
0.251
0.567
0.611
0.358
P2 M204I 0.978 0.882 0.990
P7 M204 V
L180 M
0.870
0.946
P11 M204I
L180 M
0.948
0.679
Fig. 3 Change in allele frequencies of variable sites in P1 and P2 after drug treatment (detection limit >0.01). Left panels shows the delta change
in allele frequencies of segregating sites (Y-axis) across the genome (X-axis) in patient 1 on all 3 sequencing platforms. Right panels show the
corresponding data for patient 2. All non-synonymous changes were colored in red, synonymous changes in green
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used, an issue absent in BAsE-Seq and PacBio long reads
[Additional file 1 Figure S4]. Therefore, genotype identi-
fication in Illumina libraries must take into account
evenness of coverage across the references, or number
of mismatches in mapped reads, in addition to absolute
percentage of reads mapped.
Lamivudine resistance is achieved through mutations
in the reverse transcriptase (RT) domain of the polymer-
ase gene in HBV [46–48]. Two resistance phenotypes
made up of three amino acid changes, M204I and
L180 M + M204 V, are the most commonly observed.
They confer similarly high resistance and only require
one to two nucleotide changes [49]. Both of these resist-
ant genotypes were found, and together explained resist-
ance in all four patients (Table 2). The discrepancy in
allele frequencies between the platforms may have been
due to sampling error of low viral load samples.
While P2 (M204I) and P7 (M204 V+ L180 M) carried
single resistance phenotypes, P1 carried both M204I and
M204 V+ L180 M. The genotypes are not mutually ex-
clusive and all three of the point mutations were found
in the same patient at significant frequencies (Figs. 3, 4).
P11 was nearly fixed for M204I, but also carried L180 M
at a high frequency.
Discussion
Viral Quasispecies reveal both hard and soft selective
sweeps
Single-virion haplotypes should yield deeper insights
into how these resistance genotypes evolved. Here, we
asked if we could identify whether resistance mutations
came from a single source and quickly swept to high fre-
quency (hard sweep), or multiple sources that then grew
in frequency independently (soft sweep) [50–53]. Note
that this question is extremely difficult to address with-
out long-range haplotype information. Hard sweeps are
likely to happen with lower mutation rate or extremely
strong selection, where adaptive mutations occur one at
a time and immediately outcompete other genotypes
within the population. Soft sweeps tend to dominate if
mutation rates are higher, selection is milder, population
is large [54], and multiple lineages carrying advantageous
mutations may be present at a time, all increasing in fre-
quency due to the consequent selective advantage [55,
56]. While HBV is a DNA virus that mutates relatively
slowly as compared to RNA viruses, it is also true that
Lamivudine exerts a strong selective pressure against
viral replication. We also asked if we could identify
whether resistance alleles were from de novo mutations
or from existing low frequency variants. Adaptation
from de novo mutation is usually defined as serial fix-
ation of novel alleles, with just one adaptive allele rising
to fixation at a time, whereas adaptation from standing
variation often also carries with it multiple pre-existing
mutations linked to the advantageous allele [57–60].
Which model is more relevant is partly determined by
population diversity and the presence of pre-existing
drug resistant strains. A clonal viral infection, such as a
recent or mono-strain infection seeded by very few
drug-naïve virions is less likely to carry pre-existing re-
sistance alleles as compared to a mixed infection or a
long-term infection that has had time to diversify within
the patient. There is also the possibility that a large,
highly mutable viral population could theoretically carry
all possible mutations in its quasispecies mutant pool at
any point in time. Determining the correct model for
HBV population evolution will be important for describ-
ing and modeling adaptation.
We made use of nearly full genome haplotype infor-
mation from BAsE-Seq to characterize viral population
quasi-species composition before and after drug treat-
ment (Additional file 2). PacBio trees for P1 and P2 are
Fig. 4 Change in allele frequencies of variable sites in P7 and P11
after drug treatment (detection limit >0.01). Panels show the delta
change in allele frequencies of segregating sites (Y-axis) across the
genome (X-axis) from BAsE-Seq libraries. All non-synonymous
changes were colored in red, synonymous changes in green
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available in SI. Phylogenetic trees built from viral haplo-
types revealed three different patterns in how these pa-
tients gained viral resistance (Additional file 3).
Two patients, P2 and P7, had trees that showed clear
mono-clonal gains of resistance, suggestive of hard
sweeps (Fig. 5a,b, Additional file 1 Figure S14–S15). Al-
lele frequency changes showed clusters of SNVs that in-
creased in allele frequency together (11 SNVs in P2
spanning the entire 3.2 kb sequenced region [Fig. 3] and
6 SNVs in P7 spanning 2 kb–2.8 kb [Fig. 4]). Haplotype
information confirmed that these were linked SNVs on
the same haplotype. 9/11 SNVs in the P2 cluster were
within the RT domain of the polymerase gene, and 7/11
SNVs were non-synonymous mutations within a 750 bp
window. All six SNVs in the P7 cluster were within the
RT domain of the polymerase gene, and three were non-
Fig. 5 BAsE-Seq approximately maximum-likelihood trees of viral sequences from P2 (a), P7 (b), P1 (c), and P11 (d). Tip label colors indicate if the
viral sequence came from before (black) or after (orange) drug resistance. 100 sub-sampled sequences from each timepoint are used, color-coded
by their branch labels. Bootstrap values are reflected in branch color, ranging between 0 (red) to 1 (green). Blue arrows indicate emergence of
resistance mutations. For a full phylogeny of all sequences, refer to (Additional file 1 Figures 14–17)
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synonymous mutations within a 150 bp window. These
two sweeps with numerous SNVs linked to the resist-
ance allele would support a model of evolution from
standing variation. However, these exact combinations of
SNVs were not found in the treatment naïve timepoints
for either patient. The closest haplotypes found pre-
treatment shared just 6/11 SNVs for P2 and 2/6 SNVs
for P7. Haplotype analysis of linked SNVs in PacBio se-
quences for P2 showed the same pattern (Fig. 3).
We suggest three possible explanations for this link-
age. First, there could be a detection limit for extremely
rare haplotypes in the pre-treatment timepoints. We
may simply have failed to sequence them. Second,
because our samples came from patient blood samples,
latent viral reservoirs outside of the blood stream could
be contributing to the viral population. Perhaps even
reshuffling viral haplotypes through recombination.
Again, they would be missed by serum samples. Finally,
the resistance mutation could have occurred later during
the treatment regime by chance, and happened to rise
on the background of a viral sequence that already accu-
mulated multiple nucleotide differences from the popu-
lation consensus. There was in fact a two to three fold
difference in nucleotide diversity across the eight patient
samples (Table 1), suggesting a range of quasispecies
complexity across patients, which may affect observed
evolutionary dynamics.
The two remaining patients, P1 and P11, had trees
showing at least two independent instances of gain of
resistance, in other words soft sweeps (Fig. 5c,d, SI
Additional file 1 Figure S16–S17). P1 was highly clonal
with just 6 sites shifting in frequency over time (Fig. 3),
and independently gained M204I and L180 M + M204 V
on two haplotypes. Again, this was seen in the PacBio li-
brary as well (Fig. 3). P11 carried the most diverse popu-
lation out of all four patients, starting as a mixed
population of 26% Genotype B and 74% Genotype C
(Fig. 2). The same resistance allele M204I evolved twice
on Genotype C sequences but none on Genotype B se-
quences, resulting in a resistant viral population that
was 100% Genotype C. One lineage further gained the
L180 M mutation, although it is unclear whether that
conferred additional resistance on a M204I background.
Reconstructing demographic history The BEAST ana-
lysis for P11 showed effective samples sizes (ESS) of
>500, indicating convergence. Sequences came from day
−1233 (sample before Lamivudine treatment) and day 0
(sample taken after viral resistance and consequently
viral load rebound) [SI Table 3]. Reconstructed demo-
graphic history showed an initial exponential growth
phase post infection, followed by a plateau. A sharp dip
in effective viral population size (Ne) then occurred
sometime between −1350 to −750 days prior to day 0.
Fig. 6 Overlay of BEAST reconstructed demographic history and clinical records of patient viral load (serum) for patient 11. X-axis – Timeline represented
in days, going forward in time from left to right. Green arrows point out the two timepoints that were used for single-virion sequencing. Y-
axis labeled “Viral load” – corresponding to red line tracing all available records of patient viral load (log10 scale) over time. Y-axis labeled
“BEAST Ne” - Effective population size over time as simulated by BEAST (log10 scale) shown by black line (plotted values are local medians,
with 95% highest probability density (HPD) confidence interval colored in blue)
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From actual patient viral load information, the popula-
tion crash post drug treatment occurred right after the
sample was take on day −1233. There was also a sharp
increase in median Ne about 150 days prior to day 0 in
the skyline plot, which matched clinical data almost per-
fectly (Fig. 6). Although the two major changes in popu-
lation size were well identified, a smaller increase in the
viral population size around day −700 was not, possibly
indicating some limitations when reconstructing smaller
scale changes in population demography, or that these
viruses did not contribute to the effective population
size. Due to the smaller nucleotide diversity present in
the other patient samples (Table 1), runs for P1, P2 and
P7 did not coalesce at 1E9 replications (Additional file 1
Figure S18–S20).
Conclusions
Haplotype information is vital for revealing hidden
population dynamics invisible in standard deep sequen-
cing data. While single-virion sequencing remains tech-
nically challenging, we employed two complementary
single-virion sequencing platforms to reveal – and cross-
validate - such information. We can tell, from nucleotide
diversity calculations, the heterogeneity of a population.
We can estimate, using up to thousands of single-virion
haplotypes, the relative proportions of genotypes and
quasispecies present in an infection. We can determine
if resistance evolved from a single source, or multiple
times independently. Using samples taken at different
timepoints, we can begin to explore whether evolution
occurs from standing variation or de novo mutations,
and how that is linked to quasispecies complexity. While
lamivudine resistance is a relatively simple adaptive
process with very specific alleles conferring fitness gains,
this work shows the potential of applying single-virion
sequencing to complex events such as viral response to
immune enhancement or viral dynamics during an ac-
tive HBV flare. It may also be valuable in the study of
difficult topics such as cccDNA stability, viral recombin-
ation, and viral reservoirs. Single-virion sequencing is
therefore a powerful tool for understanding the role of
viruses across disease stages of clinical importance.
Additional files
Additional file 1: A supplementary materials file provides additional
technical details and figures deemed unnecessary for the main text,
including BEAST results for all patient samples. (PDF 2754 kb)
Additional file 2: Supplementary_genomes.fasta. High quality single
virion sequences Single-virion sequences that were reconstructed with
BAsE-Seq and used in FastTree phylogeny analysis for all 4 patients.
(FASTA 1289 kb)
Additional file 3: Supplementary_FastTrees.txt. Newick format
phylogenetic trees. FastTree output in Newick format for all 4 patients
(TXT 16 kb)
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